New drug cocktail shows promise for tough lung cancer before surgery
NCT ID NCT07538193
First seen Apr 22, 2026 · Last updated May 10, 2026 · Updated 4 times
Summary
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for people with a specific type of advanced lung cancer (stage III-N2b). The goal is to see if this treatment can shrink tumors enough to improve surgery results and long-term outcomes. About 28 participants will receive three cycles of the drug combo, then undergo surgery, with follow-up to monitor their health and cancer status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial
Xi'an, Shannxi, China
Conditions
Explore the condition pages connected to this study.